Skip to main content
Log in

Large neutral amino acids in daily practice

  • Research Report
  • Published:
Journal of Inherited Metabolic Disease

Abstract

At the Kennedy Centre for Phenylketonuria, Denmark, large neutral amino acids (LNAAs) are being used to treat adult and adolescent patients who are nonadherent to dietary treatment for phenylketonuria (PKU). At the start of treatment, a patient must undergo dietary analysis and regular blood sampling to measure plasma amino acid (AA) concentrations. The aim of this analysis and treatment is that the patient receives 25–30% of the daily protein requirement from LNAA supplementation and the remaining 70–75% from natural, low-phenylalanine proteins (although some patients have difficulties in maintaining this level of protein intake). Patients are therefore able to follow a more “normal” diet than those adhering to a PKU diet with AA supplementation (in which only 20% of the daily protein requirement is provided from the diet and 80% from AA supplementation). LNAAs have also been used to treat older patients with untreated/late-diagnosed PKU who show profound intellectual, psychological, and behavioral impairments. Treatment with LNAAs has been shown to improve measures of concentration and awareness of external stimuli in some of these patients and thus enhance their socialization, emotionality, frustration tolerance, and mood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

AA:

Amino acid

LNAA:

Large neutral amino acid

OMIM:

Online Mendelian Inheritance in Man (database)

Phe:

Phenylalanine

PKU:

Phenylketonuria

t.i.d:

Three times a day

References

  • Andersen AE, Avins L (1976) Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch Neurol 33:684–686

    Article  PubMed  CAS  Google Scholar 

  • Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E (2007) Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis 30:145–152

    Article  PubMed  CAS  Google Scholar 

  • Güttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9(Suppl 2):169–177

    Article  PubMed  Google Scholar 

  • Güttler F, Wamberg E (1977) Fasting serum phenylalanine in untreated institutionalised patients with phenylketonuria. J Ment Defic Res 21:55–62

    PubMed  Google Scholar 

  • Kalkanoglu HS, Ahring KK, Sertkaya D et al (2005) Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr 94:1218–1222

    Article  PubMed  Google Scholar 

  • Lou H (1985) Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet 2:150–151

    Article  PubMed  CAS  Google Scholar 

  • Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76:560–565

    Article  PubMed  CAS  Google Scholar 

  • Matalon R, Michals-Matalon K, Bhatia G et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732–738, FF

    Article  PubMed  CAS  Google Scholar 

  • Pietz J, Kreis R, Rupp A et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103:1169–1178

    Article  PubMed  CAS  Google Scholar 

  • Scriver CR (2007) The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 28:831–845

    Article  PubMed  CAS  Google Scholar 

  • Scriver CR, Kaufman S (2001) Hyperphenylalaninemia:phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Childs B, Kinzler KW, Vogelstein B (assoc. eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, Chap. 77, pp 1667–1705

  • Smith QR, Momma S, Aoyagi M, Rapoport SI (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 49:1651–1658

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author takes full responsibility for the content of this article but thanks Caudex Medical (supported by Serono Symposia International Foundation) for their assistance in preparing the initial draft and collating the comments of the author and any other named contributors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kirsten Kiær Ahring.

Additional information

Communicated by: Nenad Blau

References to electronic database: OMIM

Competing interest: None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahring, K.K. Large neutral amino acids in daily practice. J Inherit Metab Dis 33 (Suppl 3), 187–190 (2010). https://doi.org/10.1007/s10545-010-9069-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-010-9069-7

Keywords

Navigation